Didn't find the company you were looking for? Our full system contains all Danish companies, including comprehensive credit risk reports. Register here to get started.
You can find text and video tutorials here that explain how to use our system.
Novo Nordisk Pharmatech A/S
CVR number: 13246149
Københavnsvej 216, 4600 Køge
tel: 56671000
Income statement (mDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | 620.99 | 667.73 | 619.08 | 598.26 | 880.40 |
| Other operating income | 93.11 | 142.67 | |||
| Costs of manufacturing | - 575.97 | - 829.22 | |||
| Gross profit | 149.29 | 145.87 | 150.86 | 22.30 | 51.18 |
| Costs of management | -11.37 | -15.28 | |||
| Costs of distribution | -23.19 | -29.28 | |||
| Other operating expenses | -38.98 | -58.99 | |||
| EBIT | 121.14 | 153.94 | 147.12 | 41.88 | 90.30 |
| Other financial income | 7.24 | 8.23 | |||
| Net income from associates (fin.) | 0.14 | 0.16 | |||
| Pre-tax profit | 97.30 | 114.92 | 113.75 | 49.26 | 98.69 |
| Income taxes | -9.95 | -21.44 | |||
| Net earnings | 97.30 | 114.92 | 113.75 | 39.31 | 77.25 |
Assets (mDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Land and waters | 174.46 | 255.60 | |||
| Buildings | 159.89 | 177.66 | |||
| Machinery and equipment | 27.68 | 34.43 | |||
| Advance payments and construction in progress | 99.86 | 164.45 | |||
| Tangible assets total | 461.90 | 632.14 | |||
| Holdings in group member companies | 1.30 | 1.50 | |||
| Other receivables | 809.39 | 745.52 | 639.92 | ||
| Investments total | 809.39 | 745.52 | 639.92 | 1.30 | 1.50 |
| Long term receivables total | |||||
| Finished products/goods | 352.74 | 364.15 | |||
| Inventories total | 352.74 | 364.15 | |||
| Current trade debtors | 71.73 | 64.46 | |||
| Current amounts owed by group member comp. | 56.98 | 202.65 | |||
| Prepayments and accrued income | 0.81 | 0.98 | |||
| Current other receivables | 0.07 | 0.68 | |||
| Current deferred tax assets | 21.38 | ||||
| Short term receivables total | 150.98 | 268.77 | |||
| Balance sheet total (assets) | 809.39 | 745.52 | 639.92 | 966.91 | 1 266.56 |
Equity and liabilities (mDKK)
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Share capital | 691.52 | 606.43 | 520.25 | 10.00 | 10.00 |
| Other reserves | 0.13 | 0.18 | |||
| Retained earnings | -97.30 | - 114.92 | - 113.75 | 640.18 | 679.49 |
| Profit of the financial year | 97.30 | 114.92 | 113.75 | 39.31 | 77.25 |
| Shareholders equity total | 691.52 | 606.43 | 520.25 | 689.62 | 766.91 |
| Provisions | 43.06 | 41.20 | |||
| Non-current liabilities total | |||||
| Current trade creditors | 39.14 | 48.89 | |||
| Current owed to group member | 160.76 | 326.61 | |||
| Short-term deferred tax liabilities | 5.55 | ||||
| Other non-interest bearing current liabilities | 34.33 | 77.39 | |||
| Current liabilities total | 234.23 | 458.45 | |||
| Balance sheet total (liabilities) | 691.52 | 606.43 | 520.25 | 966.91 | 1 266.56 |
Try the full version of our system for free
Create your own estimates for any company
Valuation analysis
... and more!
No registration needed.